Literature DB >> 24104872

Brain metastasis. Prognostic value of the number of involved extracranial organs.

D Rades1, L Gerdan, B Segedin, V Nagy, M T Khoa, N T Trang, S E Schild.   

Abstract

BACKGROUND AND
PURPOSE: This study was performed to evaluate the prognostic role for survival of the number and the type of involved extracranial organs in patients with brain metastasis.
MATERIAL AND METHODS: The data of 1146 patients who received whole-brain radiotherapy (WBRT) alone for brain metastasis have been retrospectively analyzed. In addition to the number of involved extra cranial organs, seven potential prognostic factors were investigated including WBRT regimen, age, gender, Karnofsky Performance Score (KPS), primary tumor type, number of brain metastases, and the interval from cancer diagnosis to WBRT. Additionally, subgroup analyses were performed for patients with involvement of one (lung vs. bone vs. liver vs. other metastasis) and two (lung + lymph nodes vs. lung + bone vs. lung + liver vs. liver + bone vs. other combinations) extracranial organs.
RESULTS: The 6-month survival rates for the involvement of 0, 1, 2, 3, and ≥4 extracranial organs were 51, 30, 16, 13, and 10%, respectively (p<0.001). On multivariate analysis, the number of involved extracranial organs maintained significance (risk ratio 1.26; 95% confidence interval 1.18-1.34; p<0.001). According to the multivariate analysis, age (p<0.001), gender (p=0.002), and KPS (p<0.001) were also independent prognostic factors for survival. In the subgroup analyses of patients with involvement of one and two extracranial organs, survival was not significantly different based on the extracranial organ involved.
CONCLUSION: The number of involved extracranial organs proved to be an independent prognostic factor in patients with brain metastasis, regardless of the organs involved. The number of involved extracranial organs should be considered in future trials designed for patients with brain metastasis.

Entities:  

Mesh:

Year:  2013        PMID: 24104872     DOI: 10.1007/s00066-013-0442-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  16 in total

1.  A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database.

Authors:  Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-10-10       Impact factor: 7.038

2.  Prognostic factors and the significance of treatment after recurrence in completely resected stage I non-small cell lung cancer.

Authors:  Yoshihisa Shimada; Hisashi Saji; Koichi Yoshida; Masatoshi Kakihana; Hidetoshi Honda; Masaharu Nomura; Jitsuo Usuda; Naohiro Kajiwara; Tatsuo Ohira; Norihiko Ikeda
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

3.  Resection plus whole-brain irradiation versus resection plus whole-brain irradiation plus boost for the treatment of single brain metastasis.

Authors:  D Rades; J D Kueter; J Gliemroth; T Veninga; A Pluemer; S E Schild
Journal:  Strahlenther Onkol       Date:  2012-01-12       Impact factor: 3.621

4.  A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104.

Authors:  K J Murray; C Scott; H M Greenberg; B Emami; M Seider; N L Vora; C Olson; A Whitton; B Movsas; W Curran
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

5.  Dose-escalation of whole-brain radiotherapy for brain metastasis in patients with a favorable survival prognosis.

Authors:  Dirk Rades; Annika Panzner; Liesa Dziggel; Tiina Haatanen; Radka Lohynska; Steven E Schild
Journal:  Cancer       Date:  2011-12-13       Impact factor: 6.860

6.  A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases.

Authors:  Dirk Rades; Juergen Dunst; Steven E Schild
Journal:  Strahlenther Onkol       Date:  2008-05       Impact factor: 3.621

7.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

8.  Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: report of RTOG trial 89-05.

Authors:  T L Phillips; C B Scott; S A Leibel; M Rotman; I J Weigensberg
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-09-30       Impact factor: 7.038

9.  Validation of a survival score for patients treated with whole-brain radiotherapy for brain metastases.

Authors:  L Dziggel; B Segedin; N H Podvrsnik; I Oblak; S E Schild; D Rades
Journal:  Strahlenther Onkol       Date:  2013-03-23       Impact factor: 3.621

10.  A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916).

Authors:  L T Komarnicky; T L Phillips; K Martz; S Asbell; S Isaacson; R Urtasun
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-01       Impact factor: 7.038

View more
  8 in total

1.  Analysis of prognostic factors and comparison of prognostic index scores in patients with brain metastases after whole-brain radiotherapy.

Authors:  Judong Luo; Hong Zhu; Yiting Tang; Honglin Wang; Xifa Zhou; Xujing Lu; Shuyu Zhang; Yunhai Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

2.  Postoperative brain metastases in soft tissue sarcomas.

Authors:  Hiroshi Urakawa; Satoshi Tsukushi; Eiji Kozawa; Kunihiro Ikuta; Shunsuke Hamada; Naoki Ishiguro; Yoshihiro Nishida
Journal:  Clin Exp Metastasis       Date:  2015-03-21       Impact factor: 5.150

3.  Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: Local tumour control and survival.

Authors:  Oliver Oehlke; David Wucherpfennig; Franziska Fels; Lars Frings; Karl Egger; Astrid Weyerbrock; Vesna Prokic; Carsten Nieder; Anca-Ligia Grosu
Journal:  Strahlenther Onkol       Date:  2015-01-16       Impact factor: 3.621

4.  Impact of systemic treatment on survival after whole brain radiotherapy in patients with brain metastases.

Authors:  Carsten Nieder; Kirsten Marienhagen; Astrid Dalhaug; Gro Aandahl; Ellinor Haukland; Adam Pawinski
Journal:  Med Oncol       Date:  2014-03-20       Impact factor: 3.064

5.  Radiosurgery to the Postoperative Tumor Bed for Metastatic Carcinoma Versus Whole Brain Radiation After Surgery.

Authors:  Kristen Scheitler-Ring; Bin Ge; Greg Petroski; Gregory Biedermann; N Scott Litofsky
Journal:  Cureus       Date:  2016-11-19

6.  External validation of a prognostic score predicting overall survival for patients with brain metastases based on extracranial factors.

Authors:  Victor Lewitzki; Rainer J Klement; Sebastian Hess; Rebekka Kosmala; Carsten Nieder; Michael Flentje
Journal:  Clin Transl Radiat Oncol       Date:  2019-02-27

7.  Computer Tomography Radiomics-Based Nomogram in the Survival Prediction for Brain Metastases From Non-Small Cell Lung Cancer Underwent Whole Brain Radiotherapy.

Authors:  Ji Zhang; Juebin Jin; Yao Ai; Kecheng Zhu; Chengjian Xiao; Congying Xie; Xiance Jin
Journal:  Front Oncol       Date:  2021-02-11       Impact factor: 6.244

8.  Prognosis of lung cancer with simple brain metastasis patients and establishment of survival prediction models: a study based on real events.

Authors:  Jiaying Yuan; Zhiyuan Cheng; Jian Feng; Chang Xu; Yi Wang; Zixiu Zou; Qiang Li; Shicheng Guo; Li Jin; Gengxi Jiang; Yan Shang; Junjie Wu
Journal:  BMC Pulm Med       Date:  2022-04-27       Impact factor: 3.317

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.